Skip to Content

Doublet immune therapy for patients with localized renal cell carcinoma at high risk of relapse after nephrectomy 

This year’s ESMO congress will present new late-breaking data for doublet immune therapy for patients with localized renal cell carcinoma. This may give hope to extending the time patients live without recurrence.

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top